

Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

Application Number	09/919,344
Filing Date	July 30, 2001
First Named Inventor	Ruth A. Pyle
Group Art Unit	1623
Examiner Name	
Attorney Docket No.	210121.543

RECEIVED

SEP 05 2002



TECH CENTER 1600/2900

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> Cited References (10) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): <u>Copy of Invitation to Pay</u> <u>Additional Fees for</u> <u>PCT/US01/23969</u>
--	---	---


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Julie A. Urvater, Ph.D. 50,461	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	8/22/02	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Monica Steinborn	
Signature		Date: 8/23/02



#5
BP
F-11
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 05 2002

Applicants : Ruth A. Pyle and Jiangchun Xu
Application No. : 09/919,344
Filed : July 30, 2001
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF PANCREATIC CANCER

TECH CENTER 1600/2900

Art Unit : 1623

Docket No. : 210121.543

COPY OF PAPERS
ORIGINALLY FILED

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 C.F.R. § 1.98, are enclosed). Documents on the attached Form PTO-1449 were cited in an Invitation to Pay Additional Search Fees for corresponding foreign application PCT/US01/23969 a copy of which is enclosed. Applicants' note that reference AC (WO 94/03597) is written in French. Accordingly, the Examiner's attention is respectfully directed to the cover page which contains an English abstract.

As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants'

duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D.
Registration No. 50,461

JAU:mls

Enclosures:

Postcard
Form PTO/SB/21
Form PTO-1449
Copies of Cited References (10)
Copy of Invitation to Pay Additional Fees for PCT/US01/23969

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.543APPLICATION NO.
09/919,344

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Ruth A. Pyle and Jiangchun Xu

FILING DATE

July 30, 2001

GROUP ART UNIT

1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AB	WO 99/67386	12/29/99	WIPO		
	AC	WO 94/03597	02/17/94	WIPO		X
	AD	WO 91/02749	03/07/91	WIPO		
	AE	EP 0376746 A2	07/04/90	EPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Alters et al., "Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells," <i>Advances in Experimental Medicine and Biology</i> 417:519-524, 1997.
AG	Database EMBL Accession Number AC035142, April 9, 2000.
AH	Database EMBL Accession Number U62099, August 3, 1996.
AI	Liao and Vorce, "Use of an alternate splice donor site in human GAP gene is responsible for synthesis of the p100 isoform," <i>Gene</i> 184:39-43, 1997.
AJ	Nair et al., "Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA," <i>Nature Biotechnology</i> 16:364-369, April 1998.
AK	Tüting et al., "Gene-based strategies for the immunotherapy of cancer," <i>Journal of Molecular Medicine</i> 75:478-491, 1997.
AL	COPY OF PAPERS ORIGINALLY FILED

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).